HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Doan's FTC Correction Requirement Is "Punitive" And "Irrational" - Novartis

This article was originally published in The Tan Sheet

Executive Summary

Novartis is asking the Federal Trade Commission to stay the corrective advertising requirement in FTC's final order in the case regarding Doan's Pills advertising claims. The firm asserts FTC's requirement for corrective ad copy is punitive in nature and "irrational" in its application for a stay of Part IV of the commission's final order and decision. FTC had concluded certain superiority claims used in Doan's ads were deceptive.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

RS140912

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel